{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:40:07Z","timestamp":1790707207392,"version":"4.1.0"},"reference-count":152,"publisher":"Informa UK Limited","issue":"11","funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2023,11,2]]},"DOI":"10.1080\/13543776.2023.2272648","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T15:16:29Z","timestamp":1697555789000},"page":"775-796","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":14,"title":["Proteasome inhibitors as anticancer agents"],"prefix":"10.1080","volume":"33","author":[{"given":"Giorgia","family":"Gazzaroli","sequence":"first","affiliation":[{"name":"Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Angeli","sequence":"additional","affiliation":[{"name":"Neurofarba Department, University of Florence, Sesto Fiorentino, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Giacomini","sequence":"additional","affiliation":[{"name":"Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Ronca","sequence":"additional","affiliation":[{"name":"Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,10,30]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.15430\/JCP.2018.23.4.153"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-021-06744-9"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.925804"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.206"},{"issue":"8","key":"e_1_3_5_7_1","first-page":"726","article-title":"The ubiquitin proteasome pathway (UPP) in the regulation of cell cycle control and DNA damage repair and its implication in tumorigenesis","volume":"5","author":"Tu Y","year":"2012","unstructured":"Tu Y, Chen C, Pan J, et al. The ubiquitin proteasome pathway (UPP) in the regulation of cell cycle control and DNA damage repair and its implication in tumorigenesis. Int J Clin Exp Pathol. 2012;5(8):726\u2013738.","journal-title":"Int J Clin Exp Pathol"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-018-0040-z"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00365-x"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2013.08.012"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.117.015370"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.6.3112"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1021\/cr0502504"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.32.22123"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s11658-020-00245-6"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2017.07.005"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2017.05.027"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-biochem-062917-011931"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-58971-4_1"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/386463a0"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf8993"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2018.03.002"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2008.03.004"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.68.1.1015"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M509043200"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.200390"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-010919-023603"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0806-4"},{"issue":"17","key":"e_1_3_5_29_1","first-page":"6316","article-title":"The proteasome as a target for cancer therapy","volume":"9","author":"Voorhees PM","year":"2003","unstructured":"Voorhees PM, Dees EC, O\u2019Neil B, et al. The proteasome as a target for cancer therapy. Clin Cancer Res. 2003;9(17):6316\u20136325.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/1010428317692248"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11010066"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12915-014-0094-0"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1042\/BST0350012"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13680"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/09603271211017972"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V104.11.4681.4681"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-009-0814-4"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100741"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.7.4.5483"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.637252"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000000703"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.4046\/trd.2008.65.6.476"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2011.43.2.124"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-019-0338-2"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.974573"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-017-3489-0"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2005.10.001"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq009"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2004.00406.x"},{"key":"e_1_3_5_51_1","unstructured":"VELCADE FDA. Food and drug administration. 2003."},{"key":"e_1_3_5_52_1","unstructured":"VELCADE EMA. European Medicines Agency. 2004."},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-019-0269-9"},{"key":"e_1_3_5_54_1","volume-title":"A phase II study of PS-341 in patients with metastatic colorectal cancer","author":"NIH","year":"2005","unstructured":"NIH. A phase II study of PS-341 in patients with metastatic colorectal cancer. National Library of Medicine; 2005."},{"key":"e_1_3_5_55_1","volume-title":"A randomized phase II trial of PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma","author":"NIH","year":"2007","unstructured":"NIH. A randomized phase II trial of PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma. National Library of Medicine; 2007."},{"key":"e_1_3_5_56_1","volume-title":"A phase II trial of PS-341 in combination with paclitaxel and carboplatin for metastatic adenocarcinoma of the lower esophagus, gastroesophageal junction, and Gastric Cardia","author":"NIH","year":"2008","unstructured":"NIH. A phase II trial of PS-341 in combination with paclitaxel and carboplatin for metastatic adenocarcinoma of the lower esophagus, gastroesophageal junction, and Gastric Cardia. National Library of Medicine; 2008."},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0144825"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2018.1529095"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.20378"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2018.02.2293"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12791"},{"key":"e_1_3_5_62_1","first-page":"102","article-title":"Ninlaro (ixazomib): first oral proteasome inhibitor approved for the treatment of patients with relapsed or refractory multiple myeloma","volume":"9","author":"Raedler LA","year":"2016","unstructured":"Raedler LA. Ninlaro (ixazomib): first oral proteasome inhibitor approved for the treatment of patients with relapsed or refractory multiple myeloma. Am Health Drug Benefits. 2016;9(Spec Feature):102\u2013105.","journal-title":"Am Health Drug Benefits"},{"key":"e_1_3_5_63_1","volume-title":"A window study of ixazomib in untreated indolent B-NHL-current","author":"NIH","unstructured":"NIH. A window study of ixazomib in untreated indolent B-NHL-current. National Library of Medicine."},{"key":"e_1_3_5_64_1","volume-title":"Phase II trial of ixazomib combined with gemcitabine and doxorubicin in patients with renal medullary carcinoma-current","author":"NIH","unstructured":"NIH. Phase II trial of ixazomib combined with gemcitabine and doxorubicin in patients with renal medullary carcinoma-current. National Library of Medicine."},{"key":"e_1_3_5_65_1","volume-title":"Phase I study of the combination of MLN9708 and fulvestrant in patients with advanced estrogen receptor positive breast cancer","author":"NIH","year":"2018","unstructured":"NIH. Phase I study of the combination of MLN9708 and fulvestrant in patients with advanced estrogen receptor positive breast cancer. National Library of Medicine; 2018."},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-100651"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2012.07.018"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.08008.x"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-62088-7"},{"issue":"6","key":"e_1_3_5_70_1","first-page":"2875","article-title":"Endoplasmic reticulum stress triggers delanzomib-induced apoptosis in HCC cells through the PERK\/eIF2\u03b1\/ATF4\/CHOP pathway","volume":"12","author":"Li J","year":"2020","unstructured":"Li J, Zhuo J-Y, Zhou W, et al. Endoplasmic reticulum stress triggers delanzomib-induced apoptosis in HCC cells through the PERK\/eIF2\u03b1\/ATF4\/CHOP pathway. Am J Transl Res. 2020;12(6):2875\u20132889.","journal-title":"Am J Transl Res"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13030"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.23166"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.12620"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1263842"},{"key":"e_1_3_5_75_1","volume-title":"An open-label study to determine the maximum tolerated dose and evaluate the safety and efficacy of CEP-18770 in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma","author":"NIH","year":"2013","unstructured":"NIH. An open-label study to determine the maximum tolerated dose and evaluate the safety and efficacy of CEP-18770 in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. National Library of Medicine; 2013."},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.09.009"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2017.07.027"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12048"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.36468\/pharmaceutical-sciences.616"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-014-0111-8"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-14-0510"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12427"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.4161\/auto.22185"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.29452"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2014.2513"},{"key":"e_1_3_5_86_1","unstructured":"FDA KYPROLIS. 2012. Food and Drug Administration."},{"key":"e_1_3_5_87_1","unstructured":"EMA KYPROLIS. 2015. European Medicines Agency."},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29999"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.183"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.5349.5349"},{"issue":"5","key":"e_1_3_5_91_1","first-page":"2347","article-title":"Next-generation proteasome inhibitor oprozomib enhances sensitivity to doxorubicin in triple-negative breast cancer cells","volume":"11","author":"Shi Y","year":"2018","unstructured":"Shi Y, Bieerkehazhi S, Ma H. Next-generation proteasome inhibitor oprozomib enhances sensitivity to doxorubicin in triple-negative breast cancer cells. Int J Clin Exp Pathol. 2018;11(5):2347\u20132355.","journal-title":"Int J Clin Exp Pathol"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9222"},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.1093\/abbs\/gmz093"},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114255"},{"key":"e_1_3_5_95_1","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.15072"},{"key":"e_1_3_5_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2018.07.003"},{"key":"e_1_3_5_97_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03927-x"},{"key":"e_1_3_5_98_1","doi-asserted-by":"publisher","DOI":"10.7150\/thno.42705"},{"key":"e_1_3_5_99_1","doi-asserted-by":"publisher","DOI":"10.1088\/2053-1591\/ac5077"},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noz126.359"},{"key":"e_1_3_5_101_1","volume-title":"Phase 2 clinical trial of NPI-0052 in patients with relapsed or relapsed\/refractory multiple myeloma, in identifier: nCT00461045","author":"NIH","year":"2014","unstructured":"NIH. Phase 2 clinical trial of NPI-0052 in patients with relapsed or relapsed\/refractory multiple myeloma, in identifier: nCT00461045. National Library of Medicine; 2014."},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-011-9766-6"},{"key":"e_1_3_5_103_1","volume-title":"NPI-0052 and vorinostat in patients with non-small cell lung cancer, pancreatic cancer, melanoma or lymphoma","author":"NIH","year":"2010","unstructured":"NIH. NPI-0052 and vorinostat in patients with non-small cell lung cancer, pancreatic cancer, melanoma or lymphoma. National Library of Medicine; 2010."},{"key":"e_1_3_5_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2012.01.003"},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(98)00030-4"},{"key":"e_1_3_5_106_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi00154a014"},{"key":"e_1_3_5_107_1","unstructured":"Stein RL MA YT Brand S. inventor; ProScript Inc. assignee. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein United States patent US 5 693 617. 1997 Dec 2."},{"key":"e_1_3_5_108_1","doi-asserted-by":"publisher","DOI":"10.1515\/hsz-2012-0212"},{"key":"e_1_3_5_109_1","doi-asserted-by":"publisher","DOI":"10.3892\/or_00000427"},{"key":"e_1_3_5_110_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom10111507"},{"key":"e_1_3_5_111_1","doi-asserted-by":"publisher","DOI":"10.3892\/or.2012.1642"},{"key":"e_1_3_5_112_1","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.201210077"},{"key":"e_1_3_5_113_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-7563.2012.01535.x"},{"key":"e_1_3_5_114_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom12010054"},{"key":"e_1_3_5_115_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M502453200"},{"key":"e_1_3_5_116_1","unstructured":"Boris Schmidt B Umbreen S Braun H et al. Technische Universit\u00e4t Charit\u00e9-Universit\u00e4tsmedizin Berlin assignee. MIMETIC PEPTIDES AND THE USE THEREOF IN THE FORM OF 20S 26S AND MMUNOPROTEASOME INHIBITORS. United States Patent US 8 835 392. inventor. 2014 Sep 16."},{"key":"e_1_3_5_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2015.06.011"},{"key":"e_1_3_5_118_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2010.01450.x"},{"key":"e_1_3_5_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2014.07.002"},{"key":"e_1_3_5_120_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2614"},{"key":"e_1_3_5_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-5521(01)00056-4"},{"key":"e_1_3_5_122_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja00545a046"},{"key":"e_1_3_5_123_1","doi-asserted-by":"publisher","DOI":"10.17352\/gjct.000007"},{"key":"e_1_3_5_124_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(03)00079-3"},{"key":"e_1_3_5_125_1","doi-asserted-by":"publisher","DOI":"10.2174\/1568009614666140804154511"},{"key":"e_1_3_5_126_1","doi-asserted-by":"publisher","DOI":"10.1186\/2050-7771-1-13"},{"key":"e_1_3_5_127_1","article-title":"Inventor; UNIV CORNELL assegnee. Artemisinin-proteasome inhibitor conjugates and their use in the treatment of disease","author":"Lin G","unstructured":"Lin G, Zhan W, Zhang H, et al. Inventor; UNIV CORNELL assegnee. Artemisinin-proteasome inhibitor conjugates and their use in the treatment of disease. WO2022159581. 2022 Jul 28.","journal-title":"WO2022159581"},{"key":"e_1_3_5_128_1","article-title":"Hoffmann-La Roche Inc. assignee. Combination theraphy with a bet inhibitor and a proteasome inhibitor","volume":"2021002309","author":"Demario MD","unstructured":"Demario MD, Friess T, Ruefli-Brasse AA. inventor; Hoffmann-La Roche Inc. assignee. Combination theraphy with a bet inhibitor and a proteasome inhibitor. United States US2021002309. 2021 Jan 28.","journal-title":"United States"},{"key":"e_1_3_5_129_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00086"},{"key":"e_1_3_5_130_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516282"},{"key":"e_1_3_5_131_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S93602"},{"key":"e_1_3_5_132_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0433"},{"key":"e_1_3_5_133_1","unstructured":"Hao F Yi Z Xuben H et al. Inventor; UNIV SHANDONG assignee. Histone deacetylase and proteasome dual-target inhibitor preparation method therefor and application thereof. W O2021115188. 2021 Jun 17."},{"key":"e_1_3_5_134_1","article-title":"GUANGZHOU VIROTECH PHARMACEUTICAL CO assignee. Use of preteasome inhibtior and alphavirus in preparation of anti-tumor medicament. United States, US20210228660","author":"Yan G","unstructured":"Yan G, Zhang H, Zhu W, et al. GUANGZHOU VIROTECH PHARMACEUTICAL CO assignee. Use of preteasome inhibtior and alphavirus in preparation of anti-tumor medicament. United States, US20210228660. inventor. 2021 Jul 29.","journal-title":"inventor"},{"key":"e_1_3_5_135_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(98)00030-4"},{"key":"e_1_3_5_136_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj2930321"},{"key":"e_1_3_5_137_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-0605"},{"key":"e_1_3_5_138_1","doi-asserted-by":"publisher","DOI":"10.1002\/anie.201005488"},{"key":"e_1_3_5_139_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.18.10403"},{"key":"e_1_3_5_140_1","doi-asserted-by":"publisher","DOI":"10.1039\/c3np20126k"},{"key":"e_1_3_5_141_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.18.10403"},{"key":"e_1_3_5_142_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja993588m"},{"key":"e_1_3_5_143_1","doi-asserted-by":"publisher","DOI":"10.2147\/PGPM.S39085"},{"key":"e_1_3_5_144_1","unstructured":"Smyth MS Laidig GJ Borchardt RT et al. inventor . Proteolix Inc. Compounds For Enzyme Inhibition. United States US20050245435. 2005 Nov 3."},{"key":"e_1_3_5_145_1","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202114502"},{"key":"e_1_3_5_146_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190902866732"},{"key":"e_1_3_5_147_1","unstructured":"Zhou HJ Laidig GJ Shenk KD et al. inventor. Proteolix Inc. Assignee. Compounds For Enzyme Inhibition. WO2008140782. 2008 Nov 20."},{"key":"e_1_3_5_148_1","article-title":"UNIV KENTUCKY RES FOUND assegnee","author":"Inventor KK","year":"2023","unstructured":"Inventor KK. UNIV KENTUCKY RES FOUND assegnee. Pro Inh. United States US11578101. 2023 Feb 14.","journal-title":"Pro Inh"},{"key":"e_1_3_5_149_1","doi-asserted-by":"publisher","DOI":"10.1002\/anie.200390115"},{"key":"e_1_3_5_150_1","doi-asserted-by":"publisher","DOI":"10.1099\/ijs.0.63625-0"},{"key":"e_1_3_5_151_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.10.013"},{"key":"e_1_3_5_152_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm900559x"},{"key":"e_1_3_5_153_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja058320b"},{"key":"e_1_3_5_154_1","article-title":"Celgene international II s\u00e0rl assignee. Use of a proteasome inhibitor for the treatment of central nervous system (CNS) cancers","author":"Trika M","unstructured":"Trika M, Levin N, Winograd B. Celgene international II s\u00e0rl assignee. Use of a proteasome inhibitor for the treatment of central nervous system (CNS) cancers. Unites States US20200085789. inventor. 2020 Mar 19.","journal-title":"Unites States US20200085789"},{"key":"e_1_3_5_155_1","unstructured":"Tello-Aburto R Rogelj S Hallada L et al. Inventor; NEW MEXICO TECH UNIV RESEARCH PARK CORPORATION assegnee. Proteasome Inhibitors. United State US11396497. 2022 Jul 26."}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2023.2272648","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T12:43:01Z","timestamp":1727268181000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2023.2272648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,30]]},"references-count":152,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11,2]]}},"alternative-id":["10.1080\/13543776.2023.2272648"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2023.2272648","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,30]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-07-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}